A Compendium on Peripheral Arterial Disease

Cooke, John P.; Chen, Zhen

doi:10.1161/circresaha.115.306403

Cited by 26 publications

(22 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was exemplified by the rapid recovery rate of 13-month-old mice, which showed a significant difference in perfusion within 7 days and a running endurance comparable to pre-surgery levels within 21 days. In studies using similar models but with younger mice (8–12 weeks old), injections of VEGF (or VEGF mimics), stem cells, or other growth factor/cytokine therapies into ischemic limbs typically resulted in 30–50% restoration of perfusion by day 28, as observed with our study controls [2,4,9,26,35–39]. In contrast, we saw close to 90% restoration of perfusion within 28 days in the older mice, which had decreased auto-regenerative and healing potential [25,40].…”

Section: Discussionsupporting

confidence: 65%

See 1 more Smart Citation

Treatment of hind limb ischemia using angiogenic peptide nanofibers

Liu²,

et al. 2016

View full text Add to dashboard Cite

For a proangiogenic therapy to be successful, it must promote the development of mature vasculature for rapid reperfusion of ischemic tissue. Whole growth factor, stem cell, and gene therapies have yet to achieve the clinical success needed to become FDA-approved revascularization therapies. Herein, we characterize a biodegradable peptide-based scaffold engineered to mimic VEGF and self-assemble into a nanofibrous, thixotropic hydrogel, SLanc. We found that this injectable hydrogel was rapidly infiltrated by host cells and could be degraded while promoting the generation of neovessels. In mice with induced hind limb ischemia, this synthetic peptide scaffold promoted angiogenesis and ischemic tissue recovery, as shown by Doppler-quantified limb perfusion and a treadmill endurance test. Thirteen-month-old mice showed significant recovery within 7 days of treatment. Biodistribution studies in healthy mice showed that the hydrogel is safe when administered intramuscularly, subcutaneously, or intravenously. These preclinical studies help establish the efficacy of this treatment for peripheral artery disease due to diminished microvascular perfusion, a necessary step before clinical translation. This peptide-based approach eliminates the need for cell transplantation or viral gene transfection (therapies currently being assessed in clinical trials) and could be a more effective regenerative medicine approach to microvascular tissue engineering.

show abstract

Section: Discussionsupporting

confidence: 65%

“…Strategies to promote blood vessel development have capitalized on stem cells and growth factors to recapitulate de novo niches for angiogenesis [1,2,4]. Current angiogenic strategies include delivering growth factors (eg, PDGF, PlGF, FGF, or VEGF) directly or via gene therapy, and administering stem cells [5–8].…”

Section: Introductionmentioning

confidence: 99%

Treatment of hind limb ischemia using angiogenic peptide nanofibers

Liu²,

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Importantly, all of those studies were cross‐sectional and could not discuss the temporality of the association. PAD can result in devastating and unique consequences, including leg pain, ulcer, and amputation as well as premature death, and its prevalence is likely to increase in the United States . Therefore, specific investigation of the impact of SES on future PAD risk would be important.…”

Section: Introductionmentioning

confidence: 99%

Socioeconomic Status and Incidence of Hospitalization With Lower‐Extremity Peripheral Artery Disease: Atherosclerosis Risk in Communities Study

Vart

Coresh

Kwak

et al. 2017

JAHA

View full text Add to dashboard Cite

BackgroundCompared to coronary heart disease, heart failure, and stroke, the relationship between low socioeconomic status (SES) and peripheral artery disease (PAD) is less well established. We examined the association between SES and incidence of hospitalization with PAD and explored whether this association can be explained by traditional cardiovascular risk factors and healthcare access.Methods and ResultsA total of 12 517 participants in the Atherosclerosis Risk in Communities (ARIC) Study (1987‐1989) with no prior PAD were examined. Individual‐level SES was assessed from household income (low <$12 000/year, medium $12 000 to $24 999/year, and high ≥$25 000/year [double to approximate to values in 2016]) and educational attainment (high school), and area‐level SES from area deprivation index (quintiles). During a median follow‐up of 23.6 (Interquartile range 19.6‐24.5) years, 433 participants had a hospitalization with PAD. In Cox proportional hazards regression analysis, the demographically adjusted hazard ratio was 2.42 (1.81‐3.23) for low household income, 2.08 (1.60‐2.69) for low educational attainment, and 2.18 (1.35‐3.53) for most deprived neighborhoods, compared to their high‐SES counterparts. After adjustment for traditional cardiovascular risk factors and heath care access, the associations were attenuated but remained significant, particularly for income and education. Results were consistent when stratified by race (P‐values for interaction >0.2 for all SES parameters).ConclusionsLow individual‐ and area‐level SES are strong predictors of hospitalization with PAD, in part due to increased prevalence of cardiovascular risk factors and poor access to care in these groups. Additional risk factors may also need to be identified and acted on to eliminate SES disparities in PAD hospitalization.

show abstract

“…2 Because of the polyvascular nature of atherosclerotic disease, PAD patients have a high risk for cardiovascular (CV) events and premature death. [3][4][5] Treatment strategies in PAD are therefore targeted against risk factors for CV events in addition to limb symptoms. Despite several sets of guidelines providing physicians with recommendations regarding best medical management, systemic vascular events are probably not optimally treated in this group of patients.…”

mentioning

confidence: 99%

“…Also, information on how pharmacologic treatment actually provided to these patients influences CV risk constitutes an important piece of the puzzle in deciding on the best medical management for the individual PAD patient. 4 This observational study aimed to describe the contemporary incidence and risk factors for CV events and mortality in a large cohort of revascularized PAD patients, retrieved from mandatory population-based registries in Sweden. It further aimed to describe the current secondary drug prevention treatment, and treatment persistence, in revascularized PAD patients in a population-based setting.…”

mentioning

confidence: 99%

Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization

Sigvant

Kragsterman

Falkenberg³

et al. 2016

Journal of Vascular Surgery

View full text Add to dashboard Cite

Revascularized PAD patients are still at a high risk for CV events without a declining time trend. A large proportion of both IC and CLI patients were not offered best medical treatment. The most commonly used agent was aspirin, which was not associated with CV event reduction. This study calls for improved medical management and highlights an important and partly unmet medical need among revascularized PAD patients.

show abstract

A Compendium on Peripheral Arterial Disease

Cited by 26 publications

References 25 publications

Treatment of hind limb ischemia using angiogenic peptide nanofibers

Treatment of hind limb ischemia using angiogenic peptide nanofibers

Socioeconomic Status and Incidence of Hospitalization With Lower‐Extremity Peripheral Artery Disease: Atherosclerosis Risk in Communities Study

Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization

Contact Info

Product

Resources

About